MA50786A - Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques - Google Patents
Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriquesInfo
- Publication number
- MA50786A MA50786A MA050786A MA50786A MA50786A MA 50786 A MA50786 A MA 50786A MA 050786 A MA050786 A MA 050786A MA 50786 A MA50786 A MA 50786A MA 50786 A MA50786 A MA 50786A
- Authority
- MA
- Morocco
- Prior art keywords
- neurological
- treatment
- combination product
- psychiatric disorders
- psychiatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382718 | 2017-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50786A true MA50786A (fr) | 2022-04-27 |
Family
ID=60382132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050786A MA50786A (fr) | 2017-10-26 | 2018-10-26 | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US11723894B2 (fr) |
| EP (1) | EP3713568A1 (fr) |
| MA (1) | MA50786A (fr) |
| WO (1) | WO2019081764A1 (fr) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11723894B2 (en) | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| DK3927338T3 (da) * | 2019-02-22 | 2025-01-06 | Gh Res Ireland Limited | Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser |
| HUE066828T2 (hu) * | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (fr) | 2019-06-19 | 2020-12-23 | GH Research Limited | Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant |
| US20210023052A1 (en) * | 2019-07-23 | 2021-01-28 | Caamtech Llc | Compositions containing toad secretion compounds |
| WO2021030571A1 (fr) * | 2019-08-13 | 2021-02-18 | University Of Maryland, Baltimore | Méthodes de traitement de troubles psychologiques et cérébraux |
| HRP20220797T1 (hr) * | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| WO2021134086A1 (fr) | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Dérivés arylcyclohexylamine et leur utilisation dans le traitement de troubles psychiatriques |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| EP3868364A1 (fr) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine |
| IL295671A (en) * | 2020-02-28 | 2022-10-01 | Universit?Tsspital Basel | Controlling effects after 5ht2a agonists administration |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| CN116056763B (zh) * | 2020-06-02 | 2024-03-05 | 赛本英国有限公司 | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 |
| WO2021116503A2 (fr) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Composés deutérés |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| BR112022025306A2 (pt) | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| EP4138818B1 (fr) * | 2020-08-28 | 2024-08-21 | Cybin UK Ltd | Formulation injectable |
| MX2023002557A (es) | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| WO2022047580A1 (fr) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Dérivés de psilocybine hydroxylés et leurs procédés d'utilisation |
| EP4221682A2 (fr) * | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Méthodes d'administration de médicaments psychédéliques par inhalation et systèmes de mise en oeuvre des méthodes |
| EP4031529B1 (fr) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4255421A1 (fr) * | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Formulations inhalables |
| CA3201913A1 (fr) | 2020-12-09 | 2022-06-16 | Andrew R. Chadeayne | Tryptamines de dialkyle et leurs utilisations therapeutiques |
| EP4126857A1 (fr) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Analogues d'ergoline |
| EP4277894A1 (fr) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Analogues de la tryptamine |
| WO2022160056A1 (fr) * | 2021-01-29 | 2022-08-04 | Algernon Pharmaceuticals Inc. | Sels de dmt et leur utilisation pour traiter une lésion cérébrale |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| WO2022204802A1 (fr) * | 2021-03-30 | 2022-10-06 | Mynd Life Sciences Inc. | Utilisation de psychédéliques pour traiter la démence |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| CA3216889A1 (fr) | 2021-04-26 | 2022-11-03 | Glenn Short | Nouvelles compositions de n,n-dimethyltryptamine et methodes |
| EP4329759A4 (fr) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | Formes cristallines de sels de lsd |
| EP4333979A4 (fr) * | 2021-05-03 | 2025-01-15 | Mind Medicine, Inc. | Procédé de titrage de doses d'agents psychédéliques |
| US12611399B2 (en) * | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| WO2022251169A1 (fr) | 2021-05-24 | 2022-12-01 | Canna-Chemistries Llc | Sels cristallins de psilocine |
| CN117642383A (zh) * | 2021-05-24 | 2024-03-01 | 卡纳-化学有限责任公司 | 二甲-4-羟色胺的结晶盐 |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| IL309210A (en) | 2021-06-09 | 2024-02-01 | Atai Therapeutics Inc | Parent drugs and conjugates of dimethyltryptamine |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| US20230064429A1 (en) | 2021-08-19 | 2023-03-02 | Mind Medicine, Inc. | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
| EP4396162A4 (fr) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | Allyl tryptamines asymétriques |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (fr) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques |
| WO2023086962A1 (fr) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybine et o-acétylpsilocine, leurs sels et formes à l'état solide |
| WO2023092044A2 (fr) | 2021-11-17 | 2023-05-25 | Terran Biosciences, Inc. | Sels de composés de phénéthylamine, formes polymorphes et leurs méthodes d'utilisation |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| AU2022413759A1 (en) * | 2021-12-13 | 2024-06-27 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| CA3238440A1 (fr) * | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Analogues de dimethyltryptamine utilises en tant que medicaments d'administration d'oxyde nitrique |
| SE2250051A1 (en) | 2022-01-20 | 2023-07-21 | Amidea Sweden Ab | New pharmaceutical composition and uses thereof |
| WO2023168023A1 (fr) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-cristaux ou sels comprenant de la psilocine |
| JP2025510368A (ja) * | 2022-03-27 | 2025-04-14 | ジーエイチ・リサーチ・アイルランド・リミテッド | 不安の処置 |
| KR20250005182A (ko) * | 2022-03-27 | 2025-01-09 | 지에이치 리서치 아일랜드 리미티드 | 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 |
| US20240000795A1 (en) * | 2022-06-30 | 2024-01-04 | Terran Biosciences Inc. | Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| EP4584247A2 (fr) * | 2022-09-06 | 2025-07-16 | ATAI Therapeutics, Inc. | Amines cycliques et alkyliques substituées par un hétéroatome en tant qu'activateurs de récepteurs de la sérotonine |
| WO2024097868A1 (fr) * | 2022-11-02 | 2024-05-10 | Caamtech, Inc. | Relations structure-activité pour psilocybine, baéocystine, aerugincine et analogues associés pour produire des effets pharmacologiques |
| CN115813917A (zh) * | 2022-11-02 | 2023-03-21 | 张樟进 | 一种具有快速改善认知功能的化合物及应用 |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| CN122477041A (zh) * | 2023-11-22 | 2026-07-28 | 吉尔伽美什制药公司 | 使用n-乙基-2-(5-氟-1h-吲哚-3-基)-n-甲基乙-1-胺或其药学上可接受的盐治疗心境障碍患者 |
| WO2025137730A1 (fr) * | 2023-12-22 | 2025-06-26 | Alexander Shulgin Research Institute, Inc. | Tryptamines n-substituées et lysergamides n-substitués et leur utilisation comme agents thérapeutiques |
| WO2026024588A1 (fr) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Compositions et traitements liés à la tryptamine à libération prolongée |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US6579899B1 (en) * | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| EP1551393A4 (fr) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| WO2008116024A2 (fr) | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinaisons d'agonistes ou antagonistes inverses de 5-ht2a avec antipsychotiques |
| US8986677B2 (en) | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| BR112015023922A2 (pt) * | 2013-03-15 | 2017-07-18 | Als Mountain Llc | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes |
| NL2018190B1 (en) | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
| US11723894B2 (en) | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| WO2021030571A1 (fr) | 2019-08-13 | 2021-02-18 | University Of Maryland, Baltimore | Méthodes de traitement de troubles psychologiques et cérébraux |
-
2018
- 2018-10-26 US US16/958,226 patent/US11723894B2/en active Active
- 2018-10-26 WO PCT/EP2018/079503 patent/WO2019081764A1/fr not_active Ceased
- 2018-10-26 EP EP18796407.7A patent/EP3713568A1/fr active Pending
- 2018-10-26 MA MA050786A patent/MA50786A/fr unknown
-
2023
- 2023-06-21 US US18/339,172 patent/US20230330063A1/en not_active Abandoned
- 2023-06-21 US US18/339,174 patent/US20240165079A1/en not_active Abandoned
-
2025
- 2025-07-21 US US19/275,394 patent/US20260183263A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11723894B2 (en) | 2023-08-15 |
| WO2019081764A1 (fr) | 2019-05-02 |
| US20230330063A1 (en) | 2023-10-19 |
| EP3713568A1 (fr) | 2020-09-30 |
| US20200397752A1 (en) | 2020-12-24 |
| US20240165079A1 (en) | 2024-05-23 |
| US20260183263A1 (en) | 2026-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3837359A4 (fr) | Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| EP3870272A4 (fr) | Stimulation nerveuse pour le traitement de la migraine et d'autres états de céphalée | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3773543A4 (fr) | Polythérapies pour le traitement de la sclérose latérale amyotrophique et de troubles apparentés | |
| EP3180022A4 (fr) | Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase | |
| MA47608A (fr) | Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3630102A4 (fr) | Formulations pour le traitement d'un trouble de stress post-traumatique | |
| EP3541408A4 (fr) | Compositions et méthodes pour le traitement de l'angiogenèse aberrante | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP3644983A4 (fr) | Compositions et méthodes de traitement ou de prévention d'affections pulmonaires fibreuses | |
| EP3728567A4 (fr) | Procédés pour le développement de produits pharmaceutiques pour le traitement d'affections neurodégénératives | |
| EP3484534A4 (fr) | Procédés et compositions de polymère pour le traitement du décollement de la rétine et d'autres troubles oculaires | |
| EP3405201A4 (fr) | Carbonate de calcium amorphe stabilisé pour le traitement de maladies ou d'affections neurologiques ou musculaires et l'infertilité | |
| EP3554626A4 (fr) | Méthodes et dispositifs destinés au traitement de troubles d'origine vasculaire | |
| EP3749322A4 (fr) | Composés et méthodes de traitement d'une dépendance et de troubles associés | |
| EP3710015A4 (fr) | Utilisation d'agents srsf3 pour le traitement et/ou la prévention d'affections neurologiques, du cancer, d'infections bactériennes ou d'infections virales | |
| EP3654961A4 (fr) | Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine | |
| EP3506927A4 (fr) | Compositions de reeline pour le traitement des troubles neurologiques | |
| EP3398614A4 (fr) | Agent pour la prévention et/ou le traitement de la maladie d'alzheimer | |
| EP3628008A4 (fr) | Compositions et méthodes pour le traitement de la maladie d'alzheimer | |
| EP3917623A4 (fr) | Compositions et méthodes pour le traitement de troubles neurocognitifs | |
| EP3996729C0 (fr) | Composition pour la prévention ou le traitement de la dépression ou de l'anxiété |